This disclosure relates to endothelial and smooth muscle like vascular tissue produced from urine cells. In certain embodiments, the disclosure relates to methods of producing endothelial and smooth muscle like vascular tissue by exposing urine derived cells with ETV2 in a first growth media under conditions such that the cells are modified to form a pool of cells expressing increased levels of endothelium surface markers and thereafter exposing the pool of cells to a second growth media under conditions such that the cells are modified to form tissue containing cells expressing increased levels of smooth muscle surface markers in addition to the endothelium surface markers. In certain embodiments, the disclosure relates to using cells and tissues reported herein for the treatment of vascular, cardiac, and wound healing indications.

The present invention relates to the field of biology and medicine, and more specifically, to the field of stem-cell biology, involving producing or generating melanocytes from stem-cells and precursors derived from human hair root. Additionally, the present invention relates to the materials and method for producing autografts, homografts or allografts comprising melanocytes in general, as well as the materials and methods for producing autografts, homografts and allografts comprising melanocytes for the treatment of diseases related to depigmentation of the skin and for the treatment of scars.

The subject matter of the invention is a functional population of human brown adipocytes, in which the expression of UCP1, CIDEA, CPT1B and Bc12 is higher, the expression of Bax is lower and the expression of PPAR-alpha, PGC-1alpha, PGC-1 beta and PRDM16 is similar compared with the corresponding expressions of a population of human white adipocytes. The invention also relates to a method for differentiation of hMADS cells into the functional population of human brown adipocytes, to a method for conversion of a population of human white adipocytes into the functional population of human brown adipocytes, and also to a method of screening for molecules capable of modulating the bodyweight in an individual.

Provided are a sanal culturing composition and a method for culturing sanal using the same.

Spheroid microtissues that can mimic native tissue-like structure and function, spheroid production methods that are high-throughput, suitable for efficient production, maintainable over long-term culture, and/or offer repeatable control over size distribution. Spheroids that have blood vessels, including spheroids with functional, blood-perfused vascular networks upon injection in vivo. Dissolvable hydrogel microwell arrays for high throughput parallel formation of spheroids in a single pipetting step and easy retrieval for downstream applications. A method to produce prevascularized microtissues in sufficient numbers to form a macrotissue in vivo for therapeutic purposes. This method is based on sacrificial release of dissolvable microwell templates, a novel and scalable strategy which enables gentle harvesting of microtissues with control over size and composition. The method forms microtissues containing endothelial cells and mesenchymal stem cells, which are co-cultured under dynamic conditions and self-organize into blood-vessel units.

The present invention relates to the discovery that different stem cell types (e.g., bone marrow-derived mesenchymal stem cells (RM-MSC) and adipose-derived mesenchymal stem cells (AT-MSC)) undergo large changes in lung epithelial marker 5 expression depending on the substrate on which they are cultured. The present invention includes methods and compositions for differentiating of mesenchymal stem cells, such as bone marrow and adipose tissue mesenchymal stem cells, into lung cells, populations of lung cells, and methods of alleviating or treating a lung defect in a subject in need thereof.

The present invention relates to organoids derived from a single cell, such as a prostate cancer cell, and methods and compositions relating to the production and use thereof, including cell culture medium for producing organoids and methods of personalized treatment for prostate cancer. The invention further provides a humanized mouse comprising a prostate organoid derived from a patient's prostate cell.

This disclosure relates to methods of treating or preventing heart malformations or cardiovascular diseases comprising administering an effective amount of thyroid hormone in combination with i) an agent that decreases DUSPS and/or DUSP6 expression and/or ii) a beta-adrenergic blocking agent to a subject in need thereof. In certain embodiments, this disclosure relates to in vivo and in vitro methods of inducing proliferation of cardiomyocytes using agents or combinations of agents disclosed herein.

The present invention relates to the discovery that different stem cell types (e.g., bone marrow-derived mesenchymal stem cells (BM-MSC) and adipose-derived mesenchymal stem cells (AT-MSC)) undergo large changes in lung epithelial marker expression depending on the substrate on which they are cultured. The present invention includes methods and compositions for differentiating of mesenchymal stem cells, such as bone marrow and adipose tissue mesenchymal stem cells, into lung cells, populations of lung cells, and methods of alleviating or treating a lung defect in a subject in need thereof.

The present disclosure pertains to compositions suitable for use in differentiating cardiac progenitor cells to cells that resemble cardiac Purkinje cells. Additional embodiments pertain to methods of generating such differentiated cardiac cells by exposing cardiac progenitor cells to the compositions. The present disclosure also pertains to methods of treating or preventing a cardiovascular disease in a subject by administering the compositions or differentiated cardiac cells to the subject. Further embodiments pertain to methods of generating a cardiac tissue by exposing cardiac progenitor cells to a composition of the present disclosure and associating the cardiac progenitor cells with a tissue scaffold. The present disclosure also pertains to the use of the differentiated cardiac progenitor cells to assess the efficacy of one or more compounds in the treatment or prevention of a cardiovascular disease. The present disclosure also pertains to the differentiated cardiac cells and cardiac tissues that include them.